Cmed and Larix fully integrate into Aixial Group
Press release – May 30th 2023
Following its acquisition of Larix in 2019 and Cmed Group in 2021, Aixial Group has become a leading mid-size, global CRO, with strong US and European presence and more than 1,000 employees.
With over 30 years’ experience in successful project delivery, Aixial Group continues to grow with the full integration of Larix and Cmed enabling it to extend its expertise and offerings, with more options for biotech and pharma sponsors at both the local and global levels. As a specialized clinical development partner, Aixial Group provides the industry with an innovative and scalable offering, which includes: comprehensive clinical trial design and execution; functional service delivery; resources and platform.
Luca Ferro, Aixial Group’s Managing Director commented: “This is a very exciting time, as after a successful transition, Cmed, and Larix have now seamlessly integrated into the Aixial Group. We offer a fresh new approach with worldwide expertise, a distinctive and flexible operating model designed to meet the demands of each phase of development, and a global delivery model created to optimize the cost and speed of any project for global biotech and pharma companies. Our reinforced expertise in oncology, cell & gene, and rare disease therapies, combined with our commitment and flexibility, enable us to deliver the most efficient clinical trials possible.”
Mr. Ferro continues: “Our mission is to empower sponsors with our expertise and efficient processes, starting from the concept stage onward. We provide support as trusted advisors and value-added experts, delivering quality work and innovation, all with a patient-centric approach. We have a proven history and will continue to employ the best talents in the industry and improve upon our processes, all to ensure sponsors around the world achieve positive outcomes for the patients who seek new treatments for their debilitating disease diagnoses.”
Following the integration, the company has now unveiled its new website, brand vision, mission and values to the industry. This combined offering is summed up by its new tagline: ‘Bringing reliability and expertise to clinical development’.
For more information and to see the new website, please visit: aixialgroup.com
Inès Touahra, Communication Officer, Aixial Group firstname.lastname@example.org
Alisha Mountford, Junior Account Executive, The Scott Partnership email@example.com
About Aixial Group
Aixial Group, the CRO solution of ALTEN Group, is a leader in CRO services with expertise in oncology, cell & gene, and rare disease therapies that spans the entire development of pharmaceuticals, biologics, and devices. Aixial Group has more than 1,000 employees worldwide providing a wide range of solutions-related CRO services including clinical operations, data management and biostatistical consulting, pharmacovigilance/drug safety, regulatory affairs, quality assurance, medical writing, and continuously expanding services in real world evidence.
About ALTEN Group
Created in 1988, ALTEN supports its customers’ development strategies in the areas of innovation, R&D and technological information systems. ALTEN works with key actors in the Aeronautics, Space, Defence, Security & Naval, Automotive, Rail & Mobility, Energy & Environment, Life Sciences & Health, Industrial Equipment & Electronics, Telecoms, Banking, Finance & Insurance, Retail, Services & Medias, Public Services & Government sectors. The Group has a workforce of more than 54,000 employees operating in 30+ countries, 88% of whom are engineers. Its 2022 turnover was €3,78 billion. For more information, visit www.alten.com